Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Louie Ngar Yee acquired 15,338 stock options in MAIA Biotechnology, Inc. on December 31, 2024.

Summary

• On December 31, 2024, Louie Ngar Yee, a director of MAIA Biotechnology, Inc., acquired 15,338 stock options.
• The stock options were granted pursuant to the company's 2021 Equity Incentive Plan.
• The options have an exercise price of $1.98.
• The options vest immediately and are exercisable from the grant date.
• The options expire on December 31, 2034.
• Following the transaction, Louie Ngar Yee directly owns 15,338 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. While insider ownership can be a positive signal, this is a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates